Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $29.78

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received an average recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $29.78.

ENGN has been the topic of a number of analyst reports. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of enGene in a research report on Monday, December 23rd. Raymond James started coverage on shares of enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, HC Wainwright assumed coverage on shares of enGene in a report on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock.

enGene Price Performance

Shares of ENGN opened at $7.39 on Friday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 1-year low of $4.42 and a 1-year high of $18.40. The firm has a market cap of $326.76 million, a PE ratio of -12.74 and a beta of -0.65. The firm has a fifty day simple moving average of $7.33 and a two-hundred day simple moving average of $7.47.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, equities analysts anticipate that enGene will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. boosted its holdings in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares in the last quarter. Franklin Resources Inc. raised its position in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new position in shares of enGene in the 3rd quarter valued at approximately $37,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.